Ginkgo Bioworks, a leader in cell programming, and Twist Bioscience Corporation, a company that offers high-quality synthetic DNA, on Tuesday announced a new supply deal that expands existing collaboration between the two companies.
Under the new four-year accord, Ginkgo Bioworks commits to buy products from Twist Bioscience, opening the door to greater capacity for synthesis to meet the growth Ginkgo has anticipated, according to a statement released by the companies.
“We love to make investments alongside incredible partners like Twist. Over the past four years, we ordered approximately one billion base pairs of synthetic DNA from Twist, allowing us to test hundreds of thousands of proteins across dozens of programs for our customers, resulting in many completed programs spanning vaccine manufacturing, food, flavor, fragrance and even cannabigerol (CBG),” said Jason Kelly, CEO of Ginkgo.
“At Twist, we work in service of our customers, like Ginkgo, who are changing the world for the better,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist.
